Markets:

Overview

News

Currencies

International

Treasuries

Dynavax Technologies Corporation - Common Stock (NQ:DVAX)

11.43 -0.01 (-0.13%)

Streaming Delayed Price Updated: 12:47 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dynavax Technologies Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

JMP Securities Maintains Market Outperform Rating for Dynavax Technologies: Here's What You Need To Know ↗

February 24, 2023

Via Benzinga

Dynavax Technologies (DVAX) Q4 2022 Earnings Call Transcript ↗

February 23, 2023

DVAX earnings call for the period ending December 31, 2022.

Via The Motley Fool

Jim Cramer On This Stock Up 2% Over 6 Months: 'You've Got A Real Winner There' ↗

January 20, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Weyerhaeuser Co (NYSE: WY) a lot.

Via Benzinga

Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023

January 15, 2023

From Clover Biopharmaceuticals

Via GlobeNewswire

The 7 Most Undervalued Long-Term Stocks to Buy in January ↗

January 14, 2023

Investors should keep an eye on these severely undervalued long-term stocks as we get deeper into New Year 2023.

Via InvestorPlace

Dynavax Technologies (DVAX) Q3 2022 Earnings Call Transcript ↗

November 03, 2022

DVAX earnings call for the period ending September 30, 2022.

Via The Motley Fool

China-Based COVID-19 Shot Neutralizes Omicron Subvariants ↗

September 20, 2022

Via Benzinga

Our 7 Top Small-Cap Stock Picks for 2023 ↗

December 12, 2022

Most of the names on this list of small-cap stock picks for 2023 are ready to rebound from a tough year in the markets.

Via InvestorPlace

Dynavax Adjuvant Based COVID-19 Vaccine Lowers The Risk Of Transmission ↗

November 30, 2022

Via Benzinga

Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases

November 30, 2022

From Clover Biopharmaceuticals

Via GlobeNewswire

Earnings Preview For Dynavax Technologies ↗

November 02, 2022

Dynavax Technologies (NASDAQ:DVAX) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

3 Under-the-Radar Small-Cap Stocks With 100% Upside Potential ↗

October 13, 2022

If under-the-radar small-cap stocks are your jam, I’ve got three selections from the S&P SmallCap 600 that might be right up your alley.

Via InvestorPlace

Clover Provides Update on 2022 Corporate Milestones

October 09, 2022

From Clover Biopharmaceuticals

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2022 ↗

September 27, 2022

Upgrades

Via Benzinga

Short Interest Sector Focus: Healthcare Sector ↗

September 26, 2022

As of the close of business on Friday, 9/23, we captured the Top 10 Highest Short Interest % stocks within the Healthcare Sector. The average short interest for stocks within the Healthcare sector...

Via Benzinga

Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday ↗

September 20, 2022

Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday.

Via Benzinga

Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary ↗

September 12, 2022

Via Benzinga

Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday's Mid-Day Session ↗

September 19, 2022

Gainers MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 134.6% to $19.74.

Via Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 25, 2022

Via Benzinga

Dynavax's Adjuvant Based COVID-19 Shot Shows Robust Immune Response, Safety In Younger Populations ↗

August 25, 2022

Hong Kong-listed Clover Biopharmaceuticals Ltd announced data from a global Phase 2/3 trial evaluating its COVID-19 vaccine candidate, SCB-2019, in adolescents (aged 12 to 17 years).

Via Benzinga

Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗

August 11, 2022

On Thursday, Rocket Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 88 to 94.

Via Investor's Business Daily

Kura Oncology Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗

August 08, 2022

On Monday, Kura Oncology stock had its Relative Strength (RS) Rating upgraded to 91, up from 85 a day earlier.

Via Investor's Business Daily

Dynavax Technologies: Q2 Earnings Insights ↗

August 04, 2022

Dynavax Technologies (NASDAQ:DVAX) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings ↗

July 26, 2022

IBD 50 member Amphastar Pharmaceuticals stock is expected to report on Aug. 9 and is trading approximately 12% below a 42.41 entry.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 25, 2022

Gainers

Via Benzinga

Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating ↗

July 15, 2022

Crispr Therapeutics sees its Relative Strength Rating enter the elite 90-plus level.

Via Investor's Business Daily

Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5 ↗

July 15, 2022

The group has several commonalities, including strong ratings and promising charts.

Via Investor's Business Daily

Prometheus Biosciences Stock Shows Rising Relative Strength ↗

July 14, 2022

Prometheus Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 72 to 90.

Via Investor's Business Daily

Merus Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗

July 14, 2022

On Thursday, Netherlands-based Merus stock had its Relative Strength (RS) Rating upgraded to 94 from 78 a day earlier.

Via Investor's Business Daily

Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗

July 13, 2022

ApellisPharmaceuticals sees its Relative Strength Rating reach the elite 90-plus level.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.